Oculis’ strategy is to employ its platform technology to develop eye drop formulations that have improved properties over approved drugs and address unmet medical needs in large, established markets.
The following table summarizes Oculis product development programs.
Oculis’ most advanced product candidate is dexamethasone cyclodextrin nanoparticle eye drops, DexNP, in two indications; diabetic macular edema (DME) and posterior/intermediate uveitis. In both instances phase 2 data show good clinical effect. DexNP has also been tested as a treatment for post-operative anti-inflammatory treatment in phase II trials demonstrating good efficacy.
Oculis has two glaucoma candidates under development. The first, OC201, has shown good results in phase II trials. The second, OC410, would belong to a new class of glaucoma drugs. OC410 is also being tested as a new treatment for diabetic retinopathy.
Oculis plans to complete pre-clinical studies for its dry-eye candidate, OC301, before year-end 2015, with phase I and phase II pilot studies conducted in 1H 2016.
In addition to the programs listed above, Oculis is in pre-clinical stage with a few other product candidates. For further information, contact us at email@example.com